Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer

Jeong-ki Kim1,2†, Ye-Young Rhee3†, Jeong Mo Bae4, Jung Ho Kim4, Seong-Joon Koh5, Hyun Jung Lee5, Jong Pil Im6, Min Jung Kim6,7, Seung-Bum Ryoo6, Seung-Yong Jeong6,7, Kyu Joo Park6, Ji Won Park6,7* and Gyeong Hoon Kang4,7*

Abstract

Background: Tumor budding is associated with lymph node (LN) metastasis in submucosal colorectal cancer (CRC). However, the rate of LN metastasis associated with the number of tumor buds is unknown. Here, we determined the optimal tumor budding cut-off number and developed a composite scoring system (CSS) for estimating LN metastasis of submucosal CRC.

Methods: In total, 395 patients with histologically confirmed T1N0–2M0 CRC were evaluated. The clinicopathological characteristics were subjected to univariate and multivariate analyses. The Akaike information criterion (AIC) values of the multivariate models were evaluated to identify the optimal cut-off number. A CSS for LN metastasis was developed using independent risk factors.

Results: The prevalence of LN metastasis was 13.2%. Histological differentiation, lymphatic or venous invasion, and tumor budding were associated with LN metastasis in univariate analyses. In multivariate models adjusted for histological differentiation and lymphatic or venous invasion, the AIC value was lowest for five tumor buds. Unfavorable differentiation (odds ratio [OR], 8.16; 95% confidence interval [CI], 1.80–36.89), lymphatic or venous invasion (OR, 5.91; 95% CI, 2.91–11.97), and five or more tumor buds (OR, 3.01; 95% CI, 1.21–7.69) were independent risk factors. In a CSS using these three risk factors, the rates of LN metastasis were 5.6%, 15.5%, 31.0%, and 52.4% for total composite scores of 0, 1, 2, and ≥ 3, respectively.

Conclusions: For the estimation of LN metastasis in submucosal CRC, the optimal tumor budding cut-off number was five. Our CSS can be utilized to estimate LN metastasis.

Keywords: Colorectal neoplasm, Histopathology, Lymph nodes metastasis, Tumor budding

Introduction

Colorectal cancer (CRC) is a major cause of cancer-associated mortality and is the most common cancer worldwide [1]. CRC can be cured by surgical treatment if detected early (stage I) without additional chemotherapy [2]. Early CRC is increasingly detected by CRC screening. In early CRC cases, malignant polyps without deep
invasion can be treated via endoscopic resection. Further radical surgery may be needed according to the probability of lymph node (LN) metastasis. The identification of risk factors for LN metastasis can assist in formulating a treatment strategy.

The prevalence of LN metastasis in submucosal CRC is 0–17.3% [3]. The risk factors for LN metastasis in submucosal CRC include histopathological features, such as lymphatic or venous invasion [4–7], poorly differentiated carcinoma [8, 9], deep submucosal invasion [9–11], and tumor budding [4–6, 12]. In addition, tumor volume, morphological features, mode of growth, absence of background adenoma, and/or lymphoid infiltration are histopathological factors associated with LN metastasis [8, 13, 14]. Tumor budding is defined as isolated single cells or clusters of up to four cells at the invasive margin [15]. Tumor budding is an adverse factor in CRC [16–20]. Furthermore, tumor budding is a predictive parameter for LN metastasis according to the guidelines of the European Society for Medical Oncology [21] and the Japanese Society for Cancer of the Colon and Rectum [22]. To our knowledge, few studies have evaluated the optimal point of tumor budding for estimating LN metastasis in submucosal CRC. Here, we determined the optimal tumor budding cut-off number and developed a scoring system to estimate LN metastasis of submucosal CRC.

Materials and methods
Study design and ethics
This was retrospective study determined the optimal tumor budding cut-off number and developed a scoring system to estimate LN metastasis of submucosal CRC. This study was reviewed and approved by the Institutional Review Board of the Seoul National University Hospital Biomedical Research Institute (approval number: H-2107–045-1232). All patients provided written informed consent and approval were obtained from all patients. All procedures were carried out in accordance with the relevant guidelines and regulations.

Patients
In total, 12,749 patients underwent surgery for CRC at Seoul National University Hospital from January 1, 2002, to December 31, 2019. Among them, patients who underwent a radical operation for submucosal CRC and had available histopathological reports were eligible for this study. Submucosal CRC was defined as an adenocarcinoma that invaded the submucosal layer and conformed to the classification guidelines of the American Joint Committee on Cancer Staging. Patients who received neoadjuvant therapy or underwent local resection were excluded. Finally, 395 patients were enrolled.

Data collection and pathological review
Data concerning patients’ clinicopathological parameters were collected from the electronic medical records. Sex, age, body mass index, American Society of Anesthesiologists score, carcinoembryonic antigen level, and tumor location were analyzed as clinical characteristics. Right colon cancer was defined as cancers in the cecum, ascending colon, and transverse colon; left colon cancer was defined as cancers in the descending and sigmoid colon; and rectal cancer was defined as tumors in the recto-sigmoid junction and the rectum [23].

Pathological features assessed were tumor histological type, lymphatic or venous invasion, perineural invasion, number of tumor buds, distance from the proximal to the distal margin, number of harvested LNs, and number of metastasized LNs. Tumors were histologically classified as favorable differentiation (well or moderately differentiated carcinoma) or unfavorable differentiation (poorly differentiated, undifferentiated, signet ring cell, or mucinous carcinoma), in accordance with the World Health Organization guidelines. Pathological features were evaluated via hematoxylin and eosin staining alone. Lymphatic or venous invasion was considered present when tumor cells invaded non-muscle-walled small vessels or large vessels with a smooth muscle layer and/or an elastic lamina layer (Fig. 1) [24]. Perineural invasion was considered present when tumor cells reached the peripheral nerve sheath layers. To objectively evaluate tumor budding, we confirmed the existence of isolated single cells or clusters of up to four cells via hematoxylin and eosin staining of tumor tissues; the number of tumor budding in a microscopic field was verified at ×200 magnification (Fig. 2). Pathological slides were assessed by three experienced gastrointestinal pathologists. The assessment of tumor budding was performed by another pathologist.

Statistical analysis
The clinical characteristics and pathological features were compared according to LN metastasis status to identify risk factors for LN metastasis. Pearson’s χ² test or Fisher’s exact test was used to compare categorical variables; Student’s t-test was used to compare continuous variables. Multivariate logistic regression analysis was performed to identify independent risk factors that were predictive of LN metastasis. We used the Akaike information criterion (AIC) of the adjusted multivariate models to identify the optimal tumor budding cut-off number. The tumor budding cut-off values, from 0 to 12 at intervals of 1, were assessed as an indicator of LN metastasis based on the AIC. The best model exhibited the lowest AIC value. The cut-off value was determined when the model had the lowest AIC value. A composite scoring system (CSS) was
developed to estimate LN metastasis by adding rounded values of the coefficients of independent risk factors. All statistical analyses were performed using SPSS 22 software (IBM Corp., Armonk, NY, USA). A \( p \)-value < 0.05 was considered statistically significant.

**Results**

The prevalence of LN metastasis was 13.2% (52/395). No clinical characteristics significantly differed between patients with and without LN metastasis (Table 1). Correlations between LN metastasis and pathological features are shown in Table 1. Tumors with LN metastasis had a higher prevalence of unfavorable differentiation \( (p = 0.022) \) and lymphatic or venous invasion \( (p < 0.001) \).

The number of buds was higher in tumors with LN metastasis than in tumors without LN metastasis \( (p = 0.001) \). Figure 3 shows the prevalence of LN metastasis and the tumor budding value. The prevalence of LN metastasis in tumors with five tumor buds was 28.6%. Tumors with five or more buds had higher rates of LN metastasis than did tumors with fewer than five tumor buds. The cut-off number was determined using the AIC from the tumor budding logistic regression models, adjusted for histological type and lymphatic or venous invasion. The AIC value was lowest (246.8) for tumors with five buds (Fig. 4). Thus, the optimal tumor budding cut-off number was five.
In a multivariate analysis using a cut-off of five, unfavorable differentiation (odds ratio [OR], 8.16; 95% confidence interval [CI], 1.80–36.89; \( p = 0.006 \)), positive lymphatic or venous invasion (OR, 5.91; 95% CI, 2.91–11.97; \( p < 0.001 \)), and tumor budding (≥5/high-power field [HPF]; OR, 3.01; 95% CI, 1.21–7.69; \( p = 0.002 \)) were significant predictive parameters for LN metastasis (Table 2). In the multivariate model, the coefficients for histological type, lymphatic or venous invasion, and tumor budding were 2.10, 1.78, and 1.10, respectively. By adding rounded coefficients, a composite score was developed (\( 2 \times \) histological type [favorable differentiation, 0; unfavorable differentiation, 1] + \( 2 \times \) lymphatic or venous invasion [negative, 0; positive, 1] + \( 1 \times \) tumor budding \[≤5/HPF, 0; ≥5/HPF, 1\]). Higher composite scores were associated with higher rates of LN metastasis (5.6%, 15.5%, 31.0%, and 52.4% for total composite scores of 0, 1, 2, and ≥3, respectively; Fig. 5).

**Discussion**

For the estimation of LN metastasis in submucosal CRC, the optimal tumor budding cut-off number was five. Imai reported that tumor budding or sprouting reflects faster tumor growth [25]. In 1989, tumor budding was defined by Morodomi as a collection of isolated cancer cells without a distinct structure (i.e., undifferentiated). Because the cells appeared to bud out from a large cancer gland, they were termed “budding” [26]. In addition, to determine the degree of budding, a pathological tissue slide was divided into four areas with dimensions of \( 500 \times 2,500 \) µm, and the mean number of buds per area was calculated [25]. The Japanese classification defines a tumor budding as an isolated single cell or cluster of cells consisting of fewer than five cells at the invasive margin of a tumor [27]. The International Tumor Budding Consensus Conference (ITBCC) established an evidence-based, standardized scoring system for CRC tumor budding, which was defined as a single cell or a cluster of ≤4 tumor cells. Tumor budding was graded using a three-tier system; scores of 0–4 indicate low budding (Bd1), 5–9 indicate intermediate budding (Bd2), and ≥10 indicate high budding (Bd3). Tumor budding is an independent predictor of LN metastasis in patients with pT1 colorectal cancer. Tumor budding is assessed in a hotspot (a field of \( 0.785 \) mm²) of the invasive front [15]. In the present study, buds were enumerated using a \( 10 \times \) ocular lens at \( 20 \times \) magnification, in accordance with the Japanese classification. The tumor budding grade according to the number of buds in a \( 0.785\)-mm² field was defined as follows: grade 1, 0–4; grade 2, 5–9; and grade 3, ≥10 [27]. A multicenter study by the Budding Investigation Project Committee of the Japanese Society for Cancer of the Colon and Rectum, in which grade 1 was defined as low

| Parameter                              | LN (-), \( n = 343 \) | LN (+), \( n = 52 \) | \( P \)   |
|----------------------------------------|-----------------------|----------------------|---------|
| Agea                                   | 63 (23–87)            | 64 (32–84)           | 0.570\(^c\) |
| Sex                                     |                       |                      |         |
| Male                                    | 225 (65.6%)           | 30 (57.7%)           | 0.340   |
| Female                                  | 118 (34.4%)           | 22 (42.3%)           |         |
| BMI \(^b\)                              |                       |                      |         |
| Mean                                    | 23.9±2.9              | 23.7±2.95            | 0.628\(^d\) |
| ASA grade                              |                       |                      |         |
| I                                       | 107 (31.2%)           | 15 (28.8%)           | 0.957   |
| II                                      | 218 (63.6%)           | 34 (65.5%)           |         |
| III                                     | 14 (4.1%)             | 2 (3.8%)             |         |
| unknown                                 | 4 (1.1%)              | 1 (1.9%)             |         |
| CEA\(^a\)                               | 1.5 (0.4–39.8)        | 1.6 (0.5–18.2)       | 0.380   |
| Location                                |                       |                      |         |
| Right colon                             | 80 (23.3%)            | 10 (19.2%)           | 0.320   |
| Left colon                              | 153 (44.6%)           | 21 (40.4%)           |         |
| Rectum                                  | 109 (31.8%)           | 20 (38.5%)           |         |
| unknown                                 | 1 (0.3%)              | 1 (1.9%)             |         |
| Histological type                       |                       |                      |         |
| Favorable                               | 321 (93.6%)           | 46 (88.5%)           | 0.022   |
| Unfavorable                             | 5 (1.5%)              | 4 (7.7%)             |         |
| unknown                                 | 17 (4.9%)             | 2 (3.8%)             |         |
| Lymphatic or venous invasion            |                       |                      |         |
| Negative                                | 304 (88.6%)           | 28 (53.8%)           | <0.001  |
| Positive                                | 36 (10.5%)            | 21 (40.4%)           |         |
| unknown                                 | 3 (0.9%)              | 3 (5.8%)             |         |
| Perineural invasion                     |                       |                      |         |
| Negative                                | 324 (94.5%)           | 48 (92.3%)           | 1.000   |
| Positive                                | 2 (0.5%)              | 0 (0%)               |         |
| unknown                                 | 17 (5.0%)             | 4 (7.7%)             |         |
| Tumor Budding                           |                       |                      |         |
| Low budding (0–4 buds)                 | 285 (83.1%)           | 31 (59.6%)           | <0.001  |
| Intermediate budding (5–9 buds)        | 33 (9.6%)             | 11 (21.2%)           |         |
| High budding (10 or more buds)         | 25 (7.3%)             | 10 (19.2%)           |         |
| Tumor budding \((n)\)                  | 0 (0–32)              | 3 (0–15)             | <0.001\(^c\) |
| Tumor size \((cm)\)                    | 1.6 (0.2–10.5)        | 1.65 (0.1–19.0)      | 0.912\(^c\) |
| Harvest LNs \((n)\)                    | 16 (0–165)            | 16 (2–46)            | 0.647\(^c\) |
| Proximal margin \((cm)\)               | 11.0 (1.4–136.0)      | 10.0 (3.5–89.0)      | 0.486\(^c\) |
| Distal margin \((cm)\)                 | 3.5 (0–75.0)          | 4.75 (0.5–48.0)      | 0.094\(^c\) |

_**Table 1** Univariate analysis of Lymph node (LN) metastasis_

_Abbreviations_: BMI Body mass index, ASA American Society of Anesthesiologists, CEA Carcinoembryonic antigen

\(^a\) Median (range);  
\(^b\) Mean ± standard error of the mean (SEM);  
\(^c\) Mann–Whitney U test;  
\(^d\) Student’s t-test
grade and grade 2/3 was defined as high grade, showed that a high grade was associated with LN metastasis [27]. When LN metastasis status was verified according to the number of tumor budding, the OR for five or more buds was 8.0 [26]. In the present study, the rate of LN metastasis increased as the number of tumor buds increased. The AIC value was lowest with five tumor buds; thus, five was the optimal cut-off value, consistent with the definition of high grade.

**Table 2** Multivariate analysis of Lymph node (LN) metastasis

| Parameter                          | OR   | 95% CI      | P    |
|------------------------------------|------|-------------|------|
| Histological type (unfavorable vs. favorable) | 8.16 | 1.80–36.89 | 0.006|
| Lymphatic or venous invasion (positive vs. negative) | 5.91 | 2.91–11.97 | <0.001|
| Tumor budding (≥ 5 vs. < 5/HPF)    | 3.01 | 1.21–7.69  | 0.002|

**Fig. 3** The prevalence of lymph node (LN) metastasis is associated with the number of tumor budding.

**Fig. 4** Akaike information criterion (AIC) in logistic regression models adjusted for histological type and lymphatic or venous invasion.
of low grade in the Japanese classification. The presence of five or more buds was independently associated with LN metastasis. The LN metastasis rate associated with high budding (≥10 buds; Bd3) was comparable to the LN metastasis rate associated with intermediate budding (5–9 buds; Bd2) (Tables S1 and S2). The impact of Bd3 status on LN metastasis was similar to the impact of Bd2 status on LN metastasis. Thus, a cut-off value of 5 is reasonable.

The histopathological predictors of LN metastasis in submucosal CRC were the depth of invasion (submucosal invasion ≥1,000 µm), unfavorable differentiation (poorly differentiated, mucinous carcinoma, or signet-ring cell carcinoma), and lymphatic or venous invasion. We confirmed that unfavorable differentiation and lymphatic or venous invasion were independent predictors in a multivariate analysis. Ryu et al. reported that lymphatic invasion and histopathological differentiation were significant risk factors in 179 patients with early CRC [28]. In a meta-analysis, lymphatic invasion was the most important predictor of LN metastasis; histological grade was also a key predictor [29]. The European Society for Medical Oncology, Japanese Society for Cancer of the Colon and Rectum, National Comprehensive Cancer Network, and Korean clinical practice guidelines recommend additional radical operations after endoscopic resection of submucosal cancer in patients with an unfavorable histological type, deep submucosal invasion, lymphatic or venous invasion, or tumor budding [21, 22, 30, 31]. We did not employ immunohistochemical staining when evaluating lymphatic or venous invasion.

Although staining of the endothelial or elastic tissues of venous walls by D2-40 (Podopalnin) or Elastica van Gieson may increase the accuracy of evaluation, these methods are not routinely employed because of the high costs and laboratory challenges imposed [32]. A limitation of the present study was that it did not confirm the depth of invasion. However, a population-based cohort study demonstrated that age <60 years, mucinous carcinoma, lymphovascular invasion, and perineural invasion were independent predictive factors, whereas deep submucosal invasion was not significant in the multivariate analysis (p=0.075), for patients with submucosal CRC undergoing a radical operation [33].

The prevalence of LN metastasis is 10–15% in patients who undergo additional operations after endoscopic resection [33–35]. In our study, the prevalence of LN metastasis was 13.2%. Most patients without LN metastasis are at risk of surgical complications. To avoid unnecessary radical surgery and failure to identify LN metastasis, a more precise predictive model for LN metastasis is needed. Several prediction models for LN metastasis in submucosal CRC have been developed [36–38]. The least absolute shrinkage and selection operator prediction model includes histopathological factors [36]; nomograms that included independent clinicopathological factors have also been used to estimate LN metastasis [37, 38]. These predictive models have good discriminatory power. We developed a simple prediction scoring system for LN metastasis that can be applied in daily clinical practice. The relative risk of LN metastasis increased as the total composite score increased. Patients with a
total composite score ≥ 2 had a LN metastasis rate > 30%. Additional surgery is recommended for these patients.

To our knowledge, this is one of few studies to investigate the optimal tumor budding cut-off number. Our work had some limitations. First, the study was retrospective in nature; selection bias may have been present. Second, the study was performed in a single institution and enrolled a small number of patients. Moreover, we did not evaluate the invasion depth when deriving risk factors. A prospective, multi-center study is needed to obtain more accurate and detailed results.

Conclusions
For the estimation of LN metastasis in submucosal CRC, the optimal tumor budding cut-off number was five. Our CSS can be utilized to estimate LN metastasis.

Abbreviations
AIC: Akaike information criterion; ASA: American Society of Anesthesiologists; BMI: Body mass index; CEA: Carcinoembryonic antigen; CI: Confidence interval; CRC: Colorectal cancer; CSS: Composite scoring system; HPF: High-power field; ITBCC: International Tumor Budding Consensus Conference; LN: Lymph node; OR: Odds ratio.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09957-8.

Additional file 1: Table S1. Lymph node (LN) metastasis status according to the three-tier system of tumor budding. Table S2. Multivariate analysis of lymph node (LN) metastasis status according to the three-tier system of tumor budding.

Acknowledgements
Not applicable.

Authors’ contributions
JJK and YYR wrote the manuscript. SJK, HIL, JPI, JMB and JHK performed some of the lab work and data collection. MJK, SBR, SYJ and KJP supported the overall data analysis and provided constructive discussion. JKK, YJR, GHK and JWP conceived and designed the study. All authors read and approved the final manuscript.

Funding
This work was supported by the Korean government (MSIT) Grant No. 2021R1F1A1063000 from the National Research Foundation of Korea (NRF).

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to ethical restrictions but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was reviewed and approved by the Institutional Review Board of the Seoul National University Hospital Biomedical Research Institute (approval number: H-2107-045-1232). Informed consent was obtained from all patients. All procedures were carried out in accordance with the relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declare that there is no conflict of interest.

Author details
1 Department of Surgery, Chung-Ang University Hospital, 06973 Seoul, Republic of Korea. 2 Chung-Ang University College of Medicine, 06973 Seoul, Republic of Korea. 3 Pathology Center, Seegene Medical Foundation, 05542 Seoul, Republic of Korea. 4 Department of Pathology, Seoul National University College of Medicine, 03080 Seoul, Republic of Korea. 5 Department of Internal Medicine, Seoul National University College of Medicine, 03080 Seoul, Republic of Korea. 6 Department of Surgery, Seoul National University College of Medicine, 03080 Seoul, Republic of Korea. 7 Cancer Research Institute, Seoul National University, 03080 Seoul, Republic of Korea.

Received: 2 December 2021 Accepted: 29 July 2022
Published online: 06 August 2022

References
1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15–36.
2. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806.
3. Beaton C, Twine CP, Williams GL, Radcliffe AG. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Colorectal Dis. 2013;15(7):788–97.
4. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127(2):385–94.
5. Tominaga K, Nakanishi Y, Nimura S, Yoshimura K, Sakai Y, Shimoda T. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. Dis Colon Rectum. 2005;48(1):92–100.
6. Sohn DK, Chang HJ, Park JW, Choi DH, Han KS, Hong CW, et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol. 2007;60(8):912–5.
7. Glasgow SC, Bleier JL, Burgart LJ, Finne CO, Lovry AC. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. J Gastrointest Surg. 2012;16(5):1019–28.
8. Suh JH, Han KS, Kim BC, Hong CW, Sohn DK, Chang HJ, et al. Predictors for lymph node metastasis in T1 colorectal cancer. Endoscopy. 2012;44(6):590–5.
9. Macias-Garcia F, Celeiro-Muñoz C, Lesquerue-Martinez L, Gude-Samperdo F, Uribarri-Gonzalez L, Abdulkader I, et al. A clinical model for predicting lymph node metastasis in submucosal invasive (T1) colorectal cancer. Int J Colorectal Dis. 2015;30(6):761–8.
10. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology. 1985;89(2):328–36.
11. Okabe S, Shia J, Nash G, Wong WD, Guilem JG, Weiher MR, et al. Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. J Gastrointest Surg. 2004;8(8):1032–9 discussion 9-40.
12. Shimomura T, Ishiguro S, Komishi H, Wakabayashi N, Mitsufuji S, Kasugai T, et al. New indication for endoscopic treatment of colorectal carcinoma with submucosal invasion. J Gastroenterol Hepatol. 2004;19(1):48–55.
13. Egashira Y, Yoshida T, Hirata L, Hamamoto N, Akutagawa H, Takeshita A, et al. Analysis of pathological risk factors for lymph node metastasis of submucosal invasive colon cancer. Mod Pathol. 2004;17(5):503–11.
14. Ogino S, Nosho K, Iba N, Meyerhardt JA, Baba Y, Shim a K, et al. Lymphoecytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15(20):6412–20.
15. Lugli A, Kirsch R, Ajikawa Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299–311.

16. Lugli A, Karamatopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br J Cancer. 2012;106(11):1713–7.

17. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25(10):1315–25.

18. van Wyk HC, Park J, Roxburgh C, Horgan P, Fouli S, McMillan DC. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treat Rev. 2015;41(2):151–9.

19. De Smedt L, Palmana S, Sagarin T. Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Arch. 2016;468(4):397–408.

20. Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer. 2016;115(7):831–40.

21. Argiélis G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–305.

22. Hashiguchi Y, Muro K, Saiato Y, Ito Y, Ajikawa Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.

23. Nishida T, Egashira Y, Akutagawa H, Fujii M, Uchiyama K, Shibayama Y, et al. Predictors of lymph node metastasis in T1 colorectal carcinoma: an immunophenotypic analysis of 265 patients. Dis Colon Rectum. 2014;57(8):905–15.

24. Kim BH, Kim JM, Kang GH, Chang HJ, Kang DW, Kim JH, et al. Standardized pathology report for colorectal cancer, 2nd edition. J Pathol Transl Med. 2020;54(1):1–19.

25. Imai T. Growth patterns in human carcinoma. Their classification and relation to prognosis. Obstet Gynecol. 1960;16:296–308.

26. Morodomi T, Isomoto H, Shirotzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63(3):539–43.

27. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajikawa Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.

28. Huh JW, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, et al. Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: predictive role of lymph node metastasis and survival. J Surg Oncol. 2014;109(8):848–52.

29. Bosch S, Teerenstra S, de Wilt JHW, Cunningham C, Nagtegaal ID. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 2013;45(10):827–41.

30. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59.

31. Ryu HS, Kim WH, Ahn S, Kim DW, Kang SB, Park HJ, et al. Combined morphologic and molecular classification for predicting lymph node metastasis in early-stage colorectal adenocarcinoma. Ann Surg Oncol. 2014;21(6):1809–16.

32. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer. Cancer Med. 2020;9(14):5095–113.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions